Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Revenues:    
Clinical laboratory services $ 15,822 $ 14,860
Product revenues 8,002 7,663
Royalty and license fee income 1,000 1,611
Total revenues 24,824 24,134
Operating expenses:    
Cost of clinical laboratory services 10,130 9,709
Cost of product revenues 3,695 3,846
Research and development 791 817
Selling, general, and administrative 10,285 10,529
Provision for uncollectible accounts receivable 541 872
Legal fee expense 2,466 1,381
Total operating expenses 27,908 27,154
Operating loss (3,084) (3,020)
Other income (expense):    
Interest (69) (62)
Other 19 61
Foreign exchange (loss) gain (472) 297
Loss before income taxes (3,606) (2,724)
Provision for income taxes (123) (63)
Net loss $ (3,729) $ (2,787)
Net loss per common share:    
Basic and diluted (in Dollars per share) $ (0.08) $ (0.07)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 44,564 41,057